BIOGEN INC (BIIB) Fundamental Analysis & Valuation

NASDAQ:BIIB • US09062X1037

182.96 USD
-1.91 (-1.03%)
Last: Mar 9, 2026, 10:10 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This BIIB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Taking everything into account, BIIB scores 5 out of 10 in our fundamental rating. BIIB was compared to 519 industry peers in the Biotechnology industry. BIIB gets an excellent profitability rating and is at the same time showing great financial health properties. BIIB is cheap, but on the other hand it scores bad on growth. These ratings could make BIIB a good candidate for value investing.


Dividend Valuation Growth Profitability Health

7

1. BIIB Profitability Analysis

1.1 Basic Checks

  • In the past year BIIB was profitable.
  • In the past year BIIB had a positive cash flow from operations.
  • In the past 5 years BIIB has always been profitable.
  • BIIB had a positive operating cash flow in each of the past 5 years.
BIIB Yearly Net Income VS EBIT VS OCF VS FCFBIIB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B

1.2 Ratios

  • BIIB has a better Return On Assets (4.39%) than 90.56% of its industry peers.
  • BIIB has a better Return On Equity (7.08%) than 91.33% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 8.93%, BIIB belongs to the top of the industry, outperforming 93.26% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for BIIB is significantly below the industry average of 19.24%.
  • The 3 year average ROIC (8.93%) for BIIB is below the current ROIC(8.93%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROIC 8.93%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
BIIB Yearly ROA, ROE, ROICBIIB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40

1.3 Margins

  • BIIB's Profit Margin of 13.07% is amongst the best of the industry. BIIB outperforms 92.10% of its industry peers.
  • In the last couple of years the Profit Margin of BIIB has declined.
  • BIIB has a better Operating Margin (27.94%) than 96.34% of its industry peers.
  • In the last couple of years the Operating Margin of BIIB has declined.
  • BIIB has a Gross Margin of 75.69%. This is amongst the best in the industry. BIIB outperforms 83.62% of its industry peers.
  • In the last couple of years the Gross Margin of BIIB has declined.
Industry RankSector Rank
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
BIIB Yearly Profit, Operating, Gross MarginsBIIB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. BIIB Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BIIB is creating some value.
  • Compared to 1 year ago, BIIB has more shares outstanding
  • BIIB has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, BIIB has an improved debt to assets ratio.
BIIB Yearly Shares OutstandingBIIB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
BIIB Yearly Total Debt VS Total AssetsBIIB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.2 Solvency

  • BIIB has an Altman-Z score of 3.31. This indicates that BIIB is financially healthy and has little risk of bankruptcy at the moment.
  • BIIB's Altman-Z score of 3.31 is fine compared to the rest of the industry. BIIB outperforms 68.40% of its industry peers.
  • The Debt to FCF ratio of BIIB is 3.11, which is a good value as it means it would take BIIB, 3.11 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.11, BIIB belongs to the top of the industry, outperforming 93.06% of the companies in the same industry.
  • BIIB has a Debt/Equity ratio of 0.34. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.34, BIIB is not doing good in the industry: 68.21% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Altman-Z 3.31
ROIC/WACC1.06
WACC8.44%
BIIB Yearly LT Debt VS Equity VS FCFBIIB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.68 indicates that BIIB has no problem at all paying its short term obligations.
  • BIIB's Current ratio of 2.68 is on the low side compared to the rest of the industry. BIIB is outperformed by 68.59% of its industry peers.
  • BIIB has a Quick Ratio of 2.03. This indicates that BIIB is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of BIIB (2.03) is worse than 74.76% of its industry peers.
Industry RankSector Rank
Current Ratio 2.68
Quick Ratio 2.03
BIIB Yearly Current Assets VS Current LiabilitesBIIB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. BIIB Growth Analysis

3.1 Past

  • The earnings per share for BIIB have decreased by -7.16% in the last year.
  • The earnings per share for BIIB have been decreasing by -14.17% on average. This is quite bad
  • The Revenue has been growing slightly by 2.22% in the past year.
  • BIIB shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -5.96% yearly.
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%

3.2 Future

  • Based on estimates for the next years, BIIB will show a small growth in Earnings Per Share. The EPS will grow by 3.53% on average per year.
  • BIIB is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -0.48% yearly.
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BIIB Yearly Revenue VS EstimatesBIIB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5B 10B
BIIB Yearly EPS VS EstimatesBIIB Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

7

4. BIIB Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 11.97, which indicates a very decent valuation of BIIB.
  • Based on the Price/Earnings ratio, BIIB is valued cheaper than 96.15% of the companies in the same industry.
  • BIIB is valuated cheaply when we compare the Price/Earnings ratio to 26.29, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 11.38, the valuation of BIIB can be described as very reasonable.
  • 97.30% of the companies in the same industry are more expensive than BIIB, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of BIIB to the average of the S&P500 Index (24.60), we can say BIIB is valued rather cheaply.
Industry RankSector Rank
PE 11.97
Fwd PE 11.38
BIIB Price Earnings VS Forward Price EarningsBIIB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • BIIB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. BIIB is cheaper than 97.30% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, BIIB is valued cheaper than 97.50% of the companies in the same industry.
Industry RankSector Rank
P/FCF 13.3
EV/EBITDA 8.13
BIIB Per share dataBIIB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 20 40 60 80 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • BIIB has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.32
PEG (5Y)N/A
EPS Next 2Y4.3%
EPS Next 3Y4.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BIIB Dividend Analysis

5.1 Amount

  • BIIB does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BIIB Fundamentals: All Metrics, Ratios and Statistics

BIOGEN INC

NASDAQ:BIIB (3/9/2026, 10:10:56 AM)

182.96

-1.91 (-1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-06
Earnings (Next)04-29
Inst Owners97.35%
Inst Owner Change5.37%
Ins Owners0.16%
Ins Owner Change7.93%
Market Cap26.85B
Revenue(TTM)9.89B
Net Income(TTM)1.29B
Analysts73.02
Price Target210.39 (14.99%)
Short Float %3.1%
Short Ratio2.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)21.18%
Min EPS beat(2)20.87%
Max EPS beat(2)21.48%
EPS beat(4)4
Avg EPS beat(4)24.64%
Min EPS beat(4)17.28%
Max EPS beat(4)38.92%
EPS beat(8)8
Avg EPS beat(8)17.2%
EPS beat(12)12
Avg EPS beat(12)12.76%
EPS beat(16)15
Avg EPS beat(16)12.81%
Revenue beat(2)2
Avg Revenue beat(2)3.75%
Min Revenue beat(2)1.26%
Max Revenue beat(2)6.23%
Revenue beat(4)4
Avg Revenue beat(4)6.45%
Min Revenue beat(4)1.26%
Max Revenue beat(4)11.62%
Revenue beat(8)6
Avg Revenue beat(8)2.98%
Revenue beat(12)9
Avg Revenue beat(12)2.26%
Revenue beat(16)11
Avg Revenue beat(16)1.92%
PT rev (1m)7.72%
PT rev (3m)15.94%
EPS NQ rev (1m)-13.19%
EPS NQ rev (3m)-11.95%
EPS NY rev (1m)5.69%
EPS NY rev (3m)4.68%
Revenue NQ rev (1m)-1.38%
Revenue NQ rev (3m)-0.78%
Revenue NY rev (1m)1.15%
Revenue NY rev (3m)1.39%
Valuation
Industry RankSector Rank
PE 11.97
Fwd PE 11.38
P/S 2.71
P/FCF 13.3
P/OCF 12.18
P/B 1.47
P/tB 10.38
EV/EBITDA 8.13
EPS(TTM)15.29
EY8.36%
EPS(NY)16.08
Fwd EY8.79%
FCF(TTM)13.76
FCFY7.52%
OCF(TTM)15.02
OCFY8.21%
SpS67.39
BVpS124.4
TBVpS17.63
PEG (NY)2.32
PEG (5Y)N/A
Graham Number206.87
Profitability
Industry RankSector Rank
ROA 4.39%
ROE 7.08%
ROCE 10.59%
ROIC 8.93%
ROICexc 10.46%
ROICexgc 35.29%
OM 27.94%
PM (TTM) 13.07%
GM 75.69%
FCFM 20.42%
ROA(3y)4.85%
ROA(5y)6.69%
ROE(3y)8.23%
ROE(5y)12.34%
ROIC(3y)8.93%
ROIC(5y)10.93%
ROICexc(3y)9.96%
ROICexc(5y)13.03%
ROICexgc(3y)38.5%
ROICexgc(5y)36.85%
ROCE(3y)10.59%
ROCE(5y)12.95%
ROICexgc growth 3Y4.85%
ROICexgc growth 5Y-4.35%
ROICexc growth 3Y-13.95%
ROICexc growth 5Y-14.37%
OM growth 3Y-3.78%
OM growth 5Y-5.27%
PM growth 3Y-24.15%
PM growth 5Y-15.17%
GM growth 3Y-0.7%
GM growth 5Y-2.57%
F-Score4
Asset Turnover0.34
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF 3.11
Debt/EBITDA 1.77
Cap/Depr 23.77%
Cap/Sales 1.87%
Interest Coverage 10.46
Cash Conversion 62.22%
Profit Quality 156.18%
Current Ratio 2.68
Quick Ratio 2.03
Altman-Z 3.31
F-Score4
WACC8.44%
ROIC/WACC1.06
Cap/Depr(3y)46.72%
Cap/Depr(5y)49.51%
Cap/Sales(3y)2.92%
Cap/Sales(5y)2.77%
Profit Quality(3y)138.91%
Profit Quality(5y)133.83%
High Growth Momentum
Growth
EPS 1Y (TTM)-7.16%
EPS 3Y-6.07%
EPS 5Y-14.17%
EPS Q2Q%-42.15%
EPS Next Y5.16%
EPS Next 2Y4.3%
EPS Next 3Y4.87%
EPS Next 5Y3.53%
Revenue 1Y (TTM)2.22%
Revenue growth 3Y-0.93%
Revenue growth 5Y-5.96%
Sales Q2Q%-7.14%
Revenue Next Year-3.98%
Revenue Next 2Y-2.43%
Revenue Next 3Y-1.25%
Revenue Next 5Y-0.48%
EBIT growth 1Y8.4%
EBIT growth 3Y-4.68%
EBIT growth 5Y-10.91%
EBIT Next Year16.69%
EBIT Next 3Y5.17%
EBIT Next 5Y1.28%
FCF growth 1Y-19.74%
FCF growth 3Y20.95%
FCF growth 5Y-11.3%
OCF growth 1Y-23.33%
OCF growth 3Y16.78%
OCF growth 5Y-12.22%

BIOGEN INC / BIIB FAQ

Can you provide the ChartMill fundamental rating for BIOGEN INC?

ChartMill assigns a fundamental rating of 5 / 10 to BIIB.


What is the valuation status of BIOGEN INC (BIIB) stock?

ChartMill assigns a valuation rating of 7 / 10 to BIOGEN INC (BIIB). This can be considered as Undervalued.


How profitable is BIOGEN INC (BIIB) stock?

BIOGEN INC (BIIB) has a profitability rating of 7 / 10.


How financially healthy is BIOGEN INC?

The financial health rating of BIOGEN INC (BIIB) is 7 / 10.